Skip to main content
Explore URMC

menu

Breast Cancer: Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy

Research Question:
What are the good and bad effects of getting more treatment with capecitabine (i.e. one of the usual approaches) compared to getting more treatment with a platinum-based chemotherapy (cisplatin or carboplatin) after surgery?

Basic Study Information

Purpose:
If you participate in this study, you will be randomized to either receive platinum-based chemotherapy for 12 weeks (you and your doctor will choose between cisplatin or carboplatin) or you will get the usual approach used for this type of cancer, capecitabine for 18 weeks.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT02445391?term=ea1131&rank=1
Study Reference #: CBRS17061

Lead Researcher (Principal Investigator)

Lead Researcher: Michelle Shayne, MD

Study Contact Information

Study Coordinator: Kate Corcoran
Phone: (585) 275-7771
Email: Kathryn_Corcoran@URMC.Rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Breast Cancer

Return to Search